back driver seat
skate puck go commit interoper soft
file remov uncertainti need reinvest
upgrad outperform
bigger ye better perhap thought utx/rtn merger
deep dive beer
quick long term trend winner stake high-end leadership
rais lower ep higher prepay greater recaptur
note meet rl
mexico tariff avert art deal
increas confid bechtel tp
evan weekli dose therapi
weekli roundup microsoft oracl snowflak azur government
stub seeker re-visit rate realiti
med-tech recap preview
live ada tvt ew lift bull/bear lunch prove
live san francisco lilli weekend updat ada somewhat
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result
investor awar firm may conflict interest could affect object report investor consid report
singl factor make invest decis
someth chew come soonwalmart refriger
lean weekend
strategi econom strategi
job report disappoint recent week weve highlight deceleratingeconomicsand
declin ratespos near-term threat equiti although cyclic data ism industri
product weaken sinc last summer job growth remain robust trend broke
nonfarm payrol print vs expect
bad news job news fed cut mani investor believ disappoint data
posit stock give fed cover cut rate work refut argument weak
read lower yield headwind regardless fed action
back driver seat
upgrad outperform
rate neutral outperform
price month
upgrad outperform pandora acquisit behind solid oper trend
net add despit y/i stabl churn despit continu arpu
growth ebitda growth acceler power buy-back cse float siri
price fallen point risk/reward opportun attract view
upsid consensu consensu ebitda fallen sinc octob
driven part new agreement expand siriusxm radio across toyota light vehicl
long-term posit despit up-front expens capital-expenditure pull-forward lower
contribut signific capital-expenditure step cse y/i bring consensu
roughli in-lin guidanc rare given management long track record beat
guidanc street tendenc anticip forecast
rais estim rebuild model post new report structur
incorpor pandora believ prior forecast conserv rais revenu
y/i adj ebitda y/i
y/i also rais revenu y/i adj ebitda
y/i y/i
attract entri point sinc announc pandora acquisit sept share
fallen vs current price trade fcf/shr
lowest valuat metric past year vs averag
valuat risk target remain base ebitda risk includ
slowdown auto sale stream competit pandora trend deterior vs
expect content cost
initi coverag boston beer co neutral rate target price beer
instabl valuat determin rate
control compani advantag rather cushion earn weak top line cost
save bbc step invest ad spend market
innovationguid time ep declin much low-end today
benefit flow new meaning innov creat growth like lead
record ep follow ep compound-annual-growth-rate
portfolio posit grow even beer woe continu model total revenu
compound-annual-growth-rate highest beer flavor malt beverag fmb repres
portfolio volum expect grow low-doubl digit medium-term driven
hard seltzer trend bbc hold lead share posit tea cider spike
seltzer volum adam remain poor portfolio ytd despit
heavi invest sinc anchor yet lift
margin opportun pushed-out step-up market spend like hidden
underli oper leverag model capac constraint commod hinder gross
margin headwind pass expect annual gross margin expans
oper margin expans out-year estim gross
margin ebitda margin recent peak margin
valuat target price base estimate ebitda
discount year-end share trade ntm ebitda peer
reflect highest expect organ growth group downsid risk continu
weak core beer segment capac constraint upsid risk fmb share gain
price month
initi coverag molson coor under-perform rate tp recent trend
challeng portfolio realiti unlik improv
price month
limit solut due consolid us busi short medium
long-term sharehold valu creation determin success failur
oper millercoor mc busi compris ebit skeptic
improv issu portfolio market manag mc abi heavili
invest two decad stabil mainstream categori premium
consecut year declin categori repres volum
thu present volum headwind higher impact profit de-lever
leverag strateg option limit model ep compound-annual-growth-rate
time bold decis make pass mc demonstr best effort align
growth segment beer innov acquisit unabl build
busi meaning overal portfolio fact high-end portfolio declin
versu industri grow
valu valu trap believ tap high free-cash-flow yield discount global beer
warrant given portfolio heavi lack emerg market exposur lever
balanc sheet estim suffici repay matur debt though
limit invest option meanwhil expect profit dollar lower
valuat target price base ev/ebitda multipl ebitda
discount global peer group trade averag ntm
ep consensu upsid risk better mainstream trend potenti
deep dive beer
quick long term trend winner
power long-term trend point shrink industri gener demograph shift
leav question us beer market trend unlik chang medium term mainstream
brand make industri volum declin annual call premium
 unlik chang examin addit secular headwind consum
drink less gener share loss wine spirit biggest brewer
highest exposur segment declin fastest young drinker prefer newer
alcbev option rise altern away-from-hom drink taproom cannabi
substitut risk debt level stifl invest
leader stake pocket growth opportun high-end segment health
well related-product outsid beer still support meaning growth boston
beer grow flavor malt beverag exposur premier high-end
portfolio first mover cannabi hold command lead segment drive market
growth view compani alreadi re-align portfolio fall behind
acceler rate
outperform abi prefer us recoveri stori top pick global beer
anheuser-busch inbev abi due strategi evolv urgent us high-
end volum revenu recent sign posit growth high-end
acceler region show modest sale growth first time yr
estim impli valuat abi america discount ev/nopat
sustain bad bettermomentum support re-rat constel deliv
healthi organ beer rev ep newco post-win divestitur even
law larg number less new distribut organ innov comp cannabi volatil
under-perform molson coor deriv us volum declin
mainstream brand estimate annual headwind portfolio concern exacerb
shrink high-end vs industri leverag nt cash flow alloc first
debt-hold limit bold acquisitions/capit invest turnaround model
neutral boston beer recent product success truli spike seltzer share
grow tripl digit add strong fmb portfolio total volum serv
off-set slump beer busi yoy despit invest yet reviv
conclus updat price channel check call large-employ commerci price
enter hard market double-digit territori meaning increas
april updat point price firm mid-single-digit territori price
momentum pronounc large-employ end marketplac rather
smid employ space compet due combin follow
retract capac large-employ insur qbe cover analyst
andrew adam us premium fm global privat premium
us premium combin control estim share
modest rise loss-expens inflat within liabil lawsuit line line
busi gear toward larg employ
higher model properti risk outlook california fire florida
assign benefit even recent reform
new interest rate persist level exist
insur portfolio yield comml insur largest sourc profit impact
everyon
lesser extent knock-on impact higher reinsur cost continu
work purchas chain
rais ep estim cb rais
april price momentum updat continu favor
insur broker rather in carrier domin fortun large-employ
marketplac ie marsh mclennan willis/wltw
top pick among larg broker way benefit harden price reflect view
large-employer-focus insur carrier experi partial margin
benefit off-set due combin higher loss-expens inflat lower interest rate
said forthright revenu commiss base
mani largest employ remain fee-bas hard
market histor caus broker client retent rate dip current near-record
level insur seek shop around polici face materi price increas
less concern potenti impact today broker control
estim large-employ space mean simpli arent mani option
switch compar past decad
rais lower ep higher
reiter outperform rate continu fall coop share come
signific pressur continu confid coop abil gener cash flow
despit increas level repay decreas book valu continu
demonstr stabil cash flow ultim deploy de-lever expect
share recov current level
rais lower ep increas core ep
estim increas
split higher origin profit lower drag fair valu mark
amort off-set higher regular amort increas
lower fair valu mark amort off-set regular amort lower
ep estim estim increas
consist core increas
reduc target price reduc target price reflect
increas risk prepay target repres ep estim
plu valu deferred-tax-asset current book valu estim risk estim
target price includ larg increas prepay activ higher-than-expect credit
note meet rl
solid execut ep lever outshin tough macro meet reinforc
view rl execut ahead target clearli nt macro risk
elev unfavor us weather tariff due us product sourc china
weak tourism hunch rl brand improv trend late much relat
execut especi europ revenu grew last quarter less
relat industri tailwind bottom line think path back sustain top-lin growth along
margin expans mid-teen ebit margin target firmli intact vs
plu big repo auth defend stock nt macro disrupt drive
consist ep deliveri potenti upsid guidance/conswhich think warrant
price-to-earnings expans year rais ep estim slightli
still room left push aur higher rl guid reli
sg leverag total ebit margin expans recent quarter nearli
guid ebit margin expans gm guid flat/down slightli fuel
investor concern gm stori could slow rl confirm continu aur/
promo reduct driver gm expans guidanc aur
msd year slower last year think due key factor rl leav
room compet current promo environ continu plan mix chang right-siz
core basic inventori value-seek consum along moder product cost cotton
freight fx pressur start confid reacceler gm stori
year
valuat tp base ep ebitda risk chang
price month
rearview mirror take step back digest data consid
discuss compani manag physician expert meet
re-evalu thesi oncolog coverag
increas tp mirati reflect recent valuat increas
likelihood success target kra first segment outperform
thesi satisfi mirati initi anticip pre-clin clinic data
continu expect stock outperform next catalyst
macrogen share investor disappoint benefit seen date margetuximab
lower estim indic decreas tp
howev maintain outperform rate thesi remain larg intact
macrogen initi see valu antibodi pipelin platform margetuximab
succeed sophia trial highlight fc optim antibodi could allow marg
beat one best-sel cancer drug histori herceptin nine total engin
antibodi clinic exampl clinic success draw investor attent
attract platform
corvu look forward first clinic efficaci data
drug appear show encourag dose-depend activ trial simpli earli
dose escal respons seen yet either mono combin therapi
base convers doctor adenosin signal hypothesi top
interest list moment like wont draw attent data matur
start yield meaning respons rate remain outperform corvu
decreas tp
increas confid bechtel tp
bechtailwind emerg sign fully-wrap lump-sum turnkey contract plan
rio grand export termin bechtel one best-respect contactor work
sector strong track record execut notabl chenier project
nois around price size facil see see addit bechtel
also take stock sign posit momentum project
process secur attent home final regulatori approv
financ importantli next set spa follow deal shell
regulatori qs disclos cost bechtel contract
larg in-lin headlin estim originally-preview
cost last year contract re-bid said appl
appl first prior cost base mtpa train new contract size
mtpa better presum return els equal higher capit call second
also includ full site prepar front would also note train size increas creat
regulatori uncertainti renew sierra club challeng regard rio grand
permit size mtpa vs new potenti mtpa train expect
address push forward train conflict still creat nois
ahead juli feder author timelin
tp tp move increas likelihood on-tim phase
fid tp base risk estim ebitda would
first year full in-servic rio grand multipl discount back
reflect discret project requir return risk sign increment spa project financ
skate puck go
commit interoper soft updat ai
surpris naysay tidepool partnership commit interoper
initi take tidepool agreement mix among attende annual meet
american diabet associ ada management clear describ clear
commit interoper word heard use often past pertain
diabet view announc signific rais confid mdt
diabet strategi reiter outperform rate target
manag deliv pipelin updat month manag highlight mdt
pipelin next month includ minim advanc hybrid close loop
system non-adjunct label guardian sensor fda submiss
next month follow person close loop pcl pump icgm-compat
sensor dispos synergi sensor month
diabet outlook look achiev manag remain confid
diabet guidanc driven dd ou growth minim instal base
growth renew medicar coverag heel non-adjunct claim
upcom event co-host expert dinner wrap-up call
cs pharma analyst vamil divan
valuat target price base ebitda multipl ebitda
bil risk product delay failur progress long-term goal potenti new litig
regulatori qualiti issu
price month
file remov uncertainti
need reinvest
multi-month delay relat investig intern misconduct account control
file friday signal expect back path toward
normal speak investor relat believ stock trade modestli
higher monday conclus intern investig reduc risk
discoveri misconduct procur divis sound like compani
believ increment cost improv intern control wont materi enough disturb
manag origin guidanc ebitda howev maintain
estim guidanc consensu take account concern busi
distract invest think compani need make manag talent
brand-build product innov tri pivot top-line growth
compani need rebuild busi acumen opinion industri
particip gener agre cutback busi resourc experienc
personnel neg impact abil navig becom increasingli challeng
busi environ find hard believ new market ceo miguel patricio
view compani exist capabl invest suffici exampl even though
prior ceo promis make major reinvest last year indic total market
spend increas advertis fell result expect increas invest
send ebitda billion compar billion
price month
bigger ye better perhap thought utx/
utx/rtn announc merger agreement utx cover rtn tp announc
agreement combin all-stock merger equal creat compani
pro forma sale rtn sharehold receiv share combin compani
post carrier spin rtn share upon complet utx sharehold hold
combin entiti rtn sharehold closur expect follow
complet utx previous announc separ carrier busi
valu creation unclear deal achiev size diversif econom benefit
seem modest see addit scale materi deepen exist moat
enhanc competit limit product overlap make cost synergi target
somewhat question view even achiev less compel net basi
rtn sale deal hrs/lll
lll sale meanwhil see rel opportun drive revenu synergi
product portfolio compani appear particularli complementari also
note neither compani own platform serv sale conduit other
product except receiv legaci col missil rtn
separ deal slide slide rtn provid guidanc
light street
rough math cover utx note estim stand-alone rtn
repres pro-forma target rtn holder receiv
less ownership contribut would suggest contribut net
debt rtn posit pension cash flow remov rtn estim pro-
forma guidanc reach contribut share equit
compar ownership split appear rtn sharehold receiv
signific premium reiter neutral rtn risk includ budget air traffic deal risk
price month
snowflak azur government looker
cloud partnership
announc new cloud interoper partnership enabl user migrat run workload
across azur oracl cloud interoper two current avail us east
plan add region futur see sign continu
willing partner vendor expand valu proposit total address
market azur servic
snowflak azur govern pr newswir snowflak announc gener
avail cloud-bas data warehous solut microsoft azur govern mark
first time snowflak made avail feder govern dedic region
meet strict govern secur complianc requir
googl announc acquisit looker bloomberg cnbc googl
announc acquisit data analyt player looker compani
largest deal sinc purchas nest lab looker acquisit expand
googl cloud offer ad platform enabl user connect collect analyz
visual data across googl cloud azur aw on-prem databas isv applic
unnam sourc claim amazon indic interest looker
busi applic summit start week host busi
applic summit june share new develop dynam
price month
stub seeker re-visit rate realiti
thought interest rate move lower across much curv believ time
right re-visit brookfield rate sensit move downward yield curv reflect
overal market concern flight rel safeti among thing given brookfield
balanc sheet larg tight spread market qualiti issu note provid
summari view group interest rate sensit continu compress yield
curv clearli favour overal valuat
stub movement week bam stub follow attribut
bbu bip bep bpi compon
med-tech recap preview
live ada tvt ew lift
bull/bear lunch prove prescient
diabet market remain dynam competit landscap diabet rapidli shift
number way sign tidepool partnership agreement commit interoper
diabet commun await approv abt libr sensor icgm result
tndm cover pivot studi evalu control-iq hybrid close loop insulin deliveri
system posit cover receiv non-adjunct label
implant sensor clear way medicar market
cs diabet expert dinner ada june san francisco co-host expert
dinner wrap-up call cs pharma analyst vamil divan pleas contact
us salesperson interest attend page wrap-up call dial-in
transcathet valv therapi jun chicago tvt import structur heart
meet focus valvular structur heart diseas expect increment updat
ew
bull/bear lunch attende lunch construct expect
stock outperform next month also view guidanc
achiev expect pipelin drive acceler attende confid
mitg brain/pain specialti therapi least confid diabet
ms index ytd bp ltm
vs univers led group week
perform lead ytd lc ms ntm ev/
ebitda vs vs last week respect
bottom line along global peer publish inventori analysi
inventori dollar report across compani dataset total inventori day
increas day q/q y/i compar post-crisi rang total semi
inventori tsi day increas day q/q y/i compar post-crisi rang
total suppli chain inv tsci day increas day q/q y/i compar
post-crisi rang vacuum high inventori alarm higher
profit level gm vr skew histor day
compar mix shift toward longer durat market bias inventori higher inventori
tend coincident/lag indic sarbanes-oxley perform howev conjunct
increas macro concern us/china/mexico/europ trade tension huawei ban high
inventori underscor junq earn like punctuat ftm estim reduct h/h
growth like better season vr street estim embed long-term
continu view us/china trade demand disloc demand destruct
distinct without differ nt addit favor resolut includ
enforc framework ip protect enhanc lt valu us semi would
elev analog/diversifi memori inventori rel sub-seg
analog/diversifi day all-tim high grew bp season dollar
actual bp season memori dollar bp season
follow bp day day q/q/y/i consid analog
inventori less concern memori inventori given lower obsolesc risk albeit still worth
suppli chain inventori elev suppli chain inventori day grew bp
season dollar declin bp season magnitud suppli chain inventori
digest robust enough valid current semi bs inventori level tariff huawei
add increment element uncertainti end-demand net/net data point suggest
semi recoveri may like one
semi like neg y/i season trend appear improv
ex-memori bp season like neg
y/i first time sinc season trend thru year impli ex-memori
y/i continu forecast semi y/i y/i ex-memori
live san francisco lilli weekend
updat ada somewhat underwhelm
bottom line attend american diabet associ ada annual meet san
francisco ca attent full result rewind cardiovascular cv
outcom trial lilli trulic addit insight emerg profil key pipelin
asset tirzepatid lilli oral semaglutid novo lilli host confer call
et monday addit data oral semaglutid tuesday morn howev
base seen far believ novo data line expect
lilli data underwhelming/disappoint lead us expect novo share rise
lilli share see weak market reopen
rewind expect investor may want trulic show
rel reduct composit mace endpoint discuss detail
session one expect base data prior cv
outcom trial figur result fairli consist across variou patient subgroup
clearli posit class although believ investor may hope
greater risk reduct think precis detail less import given growth
class driven primari care physician whose prescrib decis often less
data driven impact factor formulari posit inject devic
tirzepatid toler improv work need data trial
three differ titrat regimen provid reason optim reason caution
lilli tirzepatid slower titrat lower rate primari gastrointestin side effect
appear somewhat expect reduct initi glucos control weight
loss howev still fairli meaning rate nausea vomit
diarrhea seen patient start therapi increas dose figur lilli
util even slower titrat schedul phase surpass program toler
profil continu improv believ way go order drug
oral sema data expect focu patient payer accept detail data
vs jardianc vs victoza gener expect follow
previou top-lin data disclosur via press releas full cv outcom data
